Atyr Pharma Inc. (LIFE) Trading 2.3% Higher
Atyr Pharma Inc. (NASDAQ:LIFE) shares traded up 2.3% on Wednesday . The company traded as high as $3.18 and last traded at $3.13, with a volume of 95,281 shares changing hands. The stock had previously closed at $3.06.
A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of Atyr Pharma from a “sell” rating to a “buy” rating and set a $3.50 price objective for the company in a report on Tuesday, May 31st. JPMorgan Chase & Co. cut their price objective on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, August 11th. Finally, Citigroup Inc. lifted their price objective on shares of Atyr Pharma from $3.00 to $4.00 and gave the company a “neutral” rating in a report on Tuesday, August 16th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Atyr Pharma currently has a consensus rating of “Hold” and an average price target of $6.00.
The company’s market cap is $76.85 million. The stock’s 50 day moving average is $3.17 and its 200 day moving average is $3.53.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/14/atyr-pharma-inc-life-trading-2-3-higher.html
Atyr Pharma (NASDAQ:LIFE) last posted its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. Equities research analysts forecast that Atyr Pharma Inc. will post ($2.56) EPS for the current year.
Large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new stake in Atyr Pharma during the second quarter valued at about $101,000. A.R.T. Advisors LLC boosted its stake in Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock valued at $108,000 after buying an additional 18,410 shares in the last quarter. Bridgeway Capital Management Inc. purchased a new stake in Atyr Pharma during the second quarter valued at about $133,000. Goldman Sachs Group Inc. boosted its stake in Atyr Pharma by 220.2% in the first quarter. Goldman Sachs Group Inc. now owns 42,753 shares of the company’s stock valued at $168,000 after buying an additional 29,402 shares in the last quarter. Finally, Jackson Park Capital LLC purchased a new stake in Atyr Pharma during the second quarter valued at about $183,000. 44.75% of the stock is currently owned by institutional investors.
Atyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for Atyr Pharma Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Atyr Pharma Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.